The challenge we have is that we're seized with trying to figure out what the real problem is. Some of you are saying that the legislation isn't the real problem. Some of you are saying the governments of potential recipient countries are part of the problem. I don't buy any of this completely, but I don't reject any of it completely.
It's really going to take goodwill in terms of addressing this. When was the last time you guys--and I'm talking about the generics and the R-and-D-based pharmaceutical industries--actually met, outside of coming to a parliamentary committee, to talk about how you are going to make this work?